Viridian Therapeutics Inc
VRDN
NASDAQ
Biotechnology
$22.08
USD
+0.09 (+0.41%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.48B
Volume 1.1M
Revenue
$71.13M
TTM
+23220.3%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-386.97M
TTM
-12.5%
YoY
Operating Cash Flow
$-333.34M
TTM
-7.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.1 | 70.6 | 0.1 | 0.1 | 0.3 |
YoY Growth | +4.2% | +81958.1% | +83.3% | +95.8% | +278.7% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.1 | 70.6 | 0.1 | 0.1 | 0.3 |
Selling, General & Administrative | 20.2 | 24.3 | 33.7 | 38.7 | 55.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 |
Total Operating Expenses | 106.8 | 110.6 | 122.9 | 117.0 | 126.6 |
Operating Income | -106.8 | -40.0 | -122.7 | -116.8 | -126.3 |
EBITDA | -106.7 | -39.9 | -122.6 | -116.7 | -126.2 |
Other Income / Expense | 0.0 | 0.5 | -2.1 | 7.5 | -1.0 |
Total Other Income / Expense | 6.0 | 5.4 | 2.4 | 11.9 | -0.9 |
Income Before Income Taxes | -100.7 | -34.6 | -120.4 | -104.9 | -127.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -100.7 | -34.6 | -120.4 | -104.9 | -127.1 |
Consolidated Net Income / Loss | -100.7 | -34.6 | -120.4 | -104.9 | -127.1 |
Net Income Attributable to Common Shareholders | -82.0 | -28.2 | -101.1 | -92.0 | -112.8 |
Basic EPS | -$1.00 | -$0.34 | -$1.07 | -$0.90 | -$1.05 |
Diluted EPS | -$1.00 | -$0.34 | -$1.07 | -$0.90 | -$1.05 |
Basic Shares Outstanding | 81.6M | 81.8M | 94.5M | 102.2M | 107.9M |
Diluted Shares Outstanding | 81.6M | 81.8M | 94.5M | 102.2M | 107.9M |